pharma · Urothelial Carcinoma Bladder · Castration Resistant Metastatic Prostate Cancer · AKTS
Aktis Oncology
Aktis Oncology patent portfolio — 1 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Cambridge, USA HQ
90 Employees
Public company Type
AKTS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 90
- Programs
- 2
- Drugs
- 0
- Patents
- 1
Aktis Oncology patents
1 pharmaceutical patents indexed for Aktis Oncology. 0 expire within 24 months.
Aktis Oncology has 1 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
Frequently asked questions
How many patents does Aktis Oncology have?
1 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Aktis Oncology patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.